Zelluna ASA, a Norwegian biotech company pioneering allogeneic cell therapies for solid cancers, recently announced that the first patient has received the first dose of ZI-MA4-1 in the ZIMA-101 Phase 1 clinical trial. The treatment was administered at The Christie NHS Foundation Trust in Manchester, United Kingdom, the largest single-site cancer centre in Europe, marking […]
